Erratum to SIRT1 Protects against α-synuclein aggregation by activating molecular chaperones (The Journal of Neuroscience, (2012) 32, 1, (124-132), 10.1523/JNEUROSCI.3442-11.2012;SIRT1 protects against α-synuclein aggregation by activating molecular chaperones

Journal of Neuroscience

Volumn 32, Issue 1, 2012, Pages 124-132

  Donmez, Gizem ^a   Arun, Anirudh ^a   Chung, Chee Yeun ^c   Mclean, Pamela J ^b   Lindquist, Susan ^c   Guarente, Leonard ^a  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; CHAPERONE; SIRT1 PROTEIN, MOUSE; SIRTUIN 1; SNCA PROTEIN, MOUSE;

ANIMAL; ARTICLE; BRAIN; C57BL MOUSE; CELL INCLUSION; DISEASE MODEL; GENETICS; MALE; METABOLISM; MOUSE; MOUSE MUTANT; PHYSIOLOGICAL STRESS; PHYSIOLOGY; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; INCLUSION BODIES; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; MOLECULAR CHAPERONES; SIRTUIN 1; STRESS, PHYSIOLOGICAL;

EID: 84855929223     PISSN: 02706474     EISSN: 15292401     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.0802-16.2016     Document Type: Erratum

References (32)

1. Albani D, Polito L, Batelli S, De Mauro S, Fracasso C, Martelli G, Colombo L, Manzoni C, Salmona M, Caccia S, Negro A, Forloni G (2009) The SIRT1 activator resveratrol protects SK-N-BE cells from oxidative stress and against toxicity caused by alpha-synuclein or amyloid-beta (1-42) peptide. J Neurochem 110:1445-1456.
2. Araki T, Sasaki Y, Milbrandt J (2004) Increased nuclear NAD biosynthesis and SIRT1 activation prevent axonal degeneration. Science 305:1010-1013.
3. Arima K, Uéda K, Sunohara N, Hirai S, Izumiyama Y, Tonozuka-Uehara H, Kawai M (1998a) Immunoelectron-microscopic demonstration of NACP/alpha-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies. Brain Res 808:93-100.
4. Arima K, Uéda K, Sunohara N, Arakawa K, Hirai S, Nakamura M, Tonozuka-Uehara H, Kawai M (1998b) NACP/alpha-synuclein immunoreactivity in fibrillary components of neuronal and oligodendroglial cytoplasmic inclusions in the pontine nuclei in multiple system atrophy. Acta Neuropathol 96:439-444.
5. Auluck PK, Chan HY, Trojanowski JQ, Lee VM, Bonini NM (2002) Chaperone suppression of α -synuclein toxicity in a Drosophila model for Parkinson's disease. Science 295:865-868.
6. Bordone L, Cohen D, Robinson A, Motta MC, van Veen E, Czopik A, Steele AD, Crowe H, Marmor S, Luo J, Gu W, Guarente L (2007) SIRT1 transgenic mice show phenotypes resembling calorie restriction. Aging Cell 6:759-767.
7. Broadley SA, Hartl FU (2009) The role of molecular chaperones in human misfolding diseases. FEBS Lett 583:2647-2653.
8. Cheng HL, Mostoslavsky R, Saito S, Manis JP, Gu Y, Patel P, Bronson R, Appella E, Alt FW, Chua KF (2003) Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci U S A 100:10794-10799.
9. Cohen DE, Supinski AM, Bonkowski MS, Donmez G, Guarente LP (2009) Neuronal SIRT1 regulates endocrine and behavioral responses to calorie restriction. Genes Dev 23:2812-2817.
10. Dauer W, Przedborski S (2003) Parkinson's disease: mechanisms and models. Neuron 39:889-909.
11. Dev KK, Hofele K, Barbieri S, Buchman VL, van der Putten H (2003) Part II: α -synuclein and its molecular pathophysiological role in neurodegenerative disease. Neuropharmacology 45:14-44.
12. Donmez G, Guarente L (2010) Aging and disease: connections to sirtuins. Aging Cell 9:285-290.
13. Donmez G, Wang D, Cohen DE, Guarente L (2010) SIRT1 suppresses β-amyloid production by activating α-secretase gene ADAM10. Cell 142:320-332.
14. Eriksen JL, Dawson TM, Dickson DW, Petrucelli L (2003) Caught in the act: α synuclein is the culprit in Parkinson's disease. Neuron 40:453-456.
15. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM (2002) Neuronal α synucleinopathy with severe movement disorder in mice expressing A53T human α -synuclein. Neuron 34:521-533.
16. Haigis MC, Sinclair DA (2010) Mammalian sirtuins: biological insights and disease relevance. Annu Rev Pathol 5:253-295.
17. Jeong H, Cohen DE, Cui L, Supinski A, Savas JN, Mazzulli JR, Yates JR, Bordone L, Guarente LP, Krainc D (2011) SIRT1 mediates neuroprotection from mutant huntingtin by activation of TORC1 and CREB transcriptional pathway. Nat Med, In press.
18. Kahle PJ, Neumann M, Ozmen L, Müller V, Odoy S, Okamoto N, Jacobsen H, Iwatsubo T, Trojanowski JQ, Takahashi H, Wakabayashi K, Bogdanovic N, Riederer P, Kretzschmar HA, Haass C (2001) Selective insolubility of α -synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model. Am J Pathol 159:2215-2225.
19. Kim D, Nguyen MD, Dobbin MM, Fischer A, Sananbenesi F, Rodgers JT, Delalle I, Baur JA, Sui G, Armour SM, Puigserver P, Sinclair DA, Tsai LH (2007) SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 26:3169-3179.
20. Klucken J, Shin Y, Masliah E, Hyman BT, McLean PJ (2004) Hsp70 reduces α-synuclein aggregation and toxicity. J Biol Chem 279:25497-25502.
21. Li X, Zhang S, Blander G, Tse JG, Krieger M, Guarente L (2007) SIRT1 transgenic mice show phenotypes resembling calorie restriction. Mol Cell 28:91-106.
22. Luk KC, Mills IP, Trojanowski JQ, Lee VM (2008) Interactions between Hsp70 and the hydrophobic core of α -synuclein inhibit fibril assembly. Biochemistry 47:12614-12625.
23. McLean PJ, Klucken J, Shin Y, Hyman BT (2004) Geldanamycin induces Hsp70 and prevents α -synuclein aggregation and toxicity in vitro. Biochem Biophys Res Commun 321:665-669.
24. Min SW, Cho SH, Zhou Y, Schroeder S, Haroutunian V, Seeley WW, Huang EJ, Shen Y, Masliah E, Mukherjee C, Meyers D, Cole PA, Ott M, Gan L (2010) Acetylation of tau inhibits its degradation and contributes to taupathy. Neuron 67:953-966.
25. Morimoto RI (2008) Proteotaxic stress and inducible chaperone networks in neurodegenerative disease and aging. Genes Dev 22:1427-1438.
26. Muchowski PJ, Wacker JL (2005) Modulation of neurodegeneration by molecular chaperones. Nat Rev Neurosci 6:11-22.
27. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG (2007) Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity models of Parkinson's disease. Science 317:516-519.
28. Shimshek DR, Mueller M, Wiessner C, Schweizer T, van der Putten PH (2010) The Hsp70 molecular chaperone is not beneficial in a mouse model of α -synucleinopathy. PLoS One 5:e10014.
29. Takeda A, Hasegawa T, Matsuzaki-Kobayashi M, Sugeno N, Kikuchi A, Itoyama Y, Furukawa K (2006) Mechanisms of neuronal death in synucleinopathy. J Biomed Biotechnol 2006:19365.
30. Westerheide SD, Anckar J, Stevens SM Jr, Sistonen L, Morimoto RI (2009) Stress-inducible regulation of heat shock factor 1 by the deacetylase SIRT1. Science 323:1063-1066.
31. Yeger-Lotem E, Riva L, Su LJ, Gitler AD, Cashikar AG, King OD, Auluck PK, Geddie ML, Valastyan JS, Karger DR, Lindquist S, Fraenkel E (2009) Bridging high-throughput genetic and transcriptional data reveals cellular responses to alpha-synuclein toxicity. Nat Genet 41:316-323.
32. Yokota O, Terada S, Ishizu H, Ujike H, Ishihara T, Nakashima H, Yasuda M, Kitamura Y, Uéda K, Checler F, Kuroda S (2002) NACP/alphasynuclein, NAC, and beta-amyloid pathology of familial Alzheimer's disease with the E184D presenilin-1 mutation: a clinicopathological study of two autopsy cases. Acta Neuropathol 104:637-648.